Narcolepsy Treatments Are Advancing. Can Access?
Race, age, and other factors are linked to disparities in care for people with narcolepsy.
Tag: Avadel
All
Latest
All
Latest
Alkermes to Acquire Avadel, Adding LUMRYZ to Its Portfolio
The $2.1 billion all-cash deal will bring Avadel’s once-nightly oxybate, LUMRYZ, under Alkermes’ umbrella as it advances its orexin agonist pipeline for narcolepsy and other hypersomnolence disorders.
All
Latest
FDA Expands Approval of LUMRYZ for Pediatric Narcolepsy
The FDA has approved Avadel Pharmaceuticals' LUMRYZ for pediatric patients aged 7 and older with narcolepsy, offering a once-nightly treatment for cataplexy and excessive daytime sleepiness.
Shadows to Light Gala Recognizes Three Narcolepsy Leaders, Raises $450,000
Narcolepsy advocacy organization Wake Up Narcolepsy hosted its inaugural Shadows to Light Gala in New York City on September 20, 2024.
Read More
Lumryz Reduces Narcolepsy Symptoms, Regardless of Use of Alerting Drugs
A post-hoc analysis confirmed the efficacy of Lumryz in study participants who were and were not using a stable dose of an alerting agent.
Read More
Patient Voices Drive Push for Better Idiopathic Hypersomnia Care
A new report illuminates the real-world experiences and treatment needs of individuals with idiopathic hypersomnia.
Read More
Narcolepsy Patients Prefer Once-Nightly Lumryz Over Twice-Nightly Oxybate
Survey data demonstrate that 94% of people with narcolepsy prefer the once-nightly regimen of Lumryz over twice-nightly oxybate regimens.
Read More
Narcolepsy Medication Lumryz Linked to Weight Loss
Nearly one in five study participants treated with the extended-release sodium oxybate medication experienced clinically meaningful weight loss.
Read More
Avadel Eyes New Treatment Indications for Narcolepsy Drug Lumryz
Avadel reports advancements for Lumryz, including a phase 3 trial for idiopathic hypersomnia and an upcoming FDA decision on pediatric narcolepsy.
Read More
First Patient Dosed in Phase 3 Study of Lumryz for Idiopathic Hypersomnia
The study will evaluate the efficacy and safety of Lumryz, an extended-release sodium oxybate, as a once-at-bedtime treatment for idiopathic hypersomnia.
Read More
Avadel to Present New Data on Lumryz for Narcolepsy at SLEEP 2024
Avadel will present a series of new analyses highlighting the efficacy, safety, and patient preference for Lumryz, a once-nightly, extended-release formulation of sodium oxybate.
Read More
Avadel Reports Uptick in Lumryz Therapy Adoption for Narcolepsy in Q1
Patient usage of Lumryz in increased 70% in Q1, while Avadel plans to expand into pediatric treatment and launch a phase 3 trial in idiopathic hypersomnia.
Read More
Jazz and Avadel Both Secure Wins in Patent Lawsuit Over Narcolepsy Drug
A jury from the United States District Court for the District of Delaware delivered a mixed verdict in a patent lawsuit between Jazz Pharmaceuticals Inc and Avadel Pharmaceuticals plc concerning Avadel’s narcolepsy medication Lumryz.
Read More
Once-Nightly Lumryz Attracts Over 1,200 Narcolepsy Patients Since June Launch
Avadel Pharmaceuticals’ CEO says the “meaningful increase” in patients initiating therapy underscores the unmet need for a once-at-bedtime therapy.
Read More
How to Select the Most Suitable Pharmacotherapy for Type 1 Narcolepsy Patients
Sleep specialists share practical tips on choosing medications that treat narcolepsy symptoms, including excessive daytime sleepiness and cataplexy.
Read More
Lumryz Gains Ground in Narcolepsy Treatment, Reports Avadel
Avadel Pharmaceuticals shared updates on the performance and reception of its new narcolepsy medication, Lumryz, a once-at-bedtime extended-release sodium oxybate medication that has been on the market since June 2023.
Read More
Avadel to Present Data Supporting Once-Nightly Lumryz for Narcolepsy
Avadel Pharmaceuticals announced new and encore data abstracts emphasizing the clinical benefit of Lumryz and patient preference for a once-at-bedtime narcolepsy treatment option.
Read More
Avadel Prepares to Seek FDA Approval of Lumryz in Pediatric Population
Avadel aims to expand the potential of Lumryz with a supplemental New Drug Application filing planned in the second half of 2023 for Lumryz in the pediatric narcolepsy population.
Read More